AI and Precision Medicine in Solid Tumors
AI and Precision Medicine in Solid Tumors
The webinar “AI and Precision Medicine in Solid Tumors” has already taken place. However, for those interested in the valuable insights shared during this event, the recorded discussion is now available.
Key topics covered in the webinar included:
-
Imaging endpoints in oncology and regulatory requirements
-
Site vs central reading: benefits, challenges, and opportunities
-
Assessment criteria in solid tumors: choosing the right criteria
-
Volumetrics and radiomics in solid tumors
The expert presenters were:
-
Dr. Anitha Singareddy: A board-certified physician with over 13 years of experience in clinical research, CRO industry, and medical imaging, particularly in solid tumor portfolio using RECIST 1.1, iRECIST, and other oncology review criteria.
-
Dr. Andrew Patterson: An experienced researcher with over 70 papers focusing on the development of novel imaging biomarkers and expertise in selecting optimal imaging and AI strategies to accelerate drug development.
The discussion was moderated by Julia O’Lynn, who has 20+ years of expertise in targeted drug development and advanced radiologic imaging.
For those who missed the live event, you can access the recorded webinar by contacting Image Analysis Group (IAG) directly. IAG is a leading partner to life sciences companies, specializing in AI-powered drug development and precision medicine. They leverage their proprietary cloud-based platform, Dynamika™, to de-risk clinical development and accelerate the delivery of lifesaving therapies.
To request access to the webinar recording or for more information about IAG’s services in AI-powered drug development and precision medicine, please contact IAG directly through their website or official channels.